Peptides for Gut Health: BPC-157, KPV, and LL-37

Gut health issues — from inflammatory bowel disease and leaky gut to chronic gastritis and slow-healing ulcers — are among the most common reasons people explore peptide therapy. Three peptides have emerged as the most studied and used for gastrointestinal applications: BPC-157 for tissue repair, KPV for anti-inflammatory modulation, and LL-37 for antimicrobial defense. Each targets a different aspect of gut dysfunction.

BPC-157 is the most widely studied peptide for gastrointestinal healing. Derived from a protein in human gastric juice, it has a natural affinity for gut tissue and — uniquely among peptides — is stable in stomach acid, making oral administration viable.

Animal studies have shown BPC-157 accelerates healing of gastric ulcers, repairs damage from NSAID use (a common cause of gut lining erosion), reduces inflammation in models of inflammatory bowel disease, and protects against alcohol-induced gastric damage.

For gut applications, BPC-157 is typically taken orally at 250-500 mcg twice daily on an empty stomach. Some protocols use subcutaneous injection into the abdominal area at 250-500 mcg daily. The oral route is preferred for upper GI issues (stomach, duodenum) while injection may be better for lower GI conditions.

KPV is a tripeptide (Lys-Pro-Val) derived from alpha-melanocyte stimulating hormone (α-MSH). It has potent anti-inflammatory effects specifically relevant to the gut: it inhibits NF-κB signaling (a master inflammatory pathway), reduces production of pro-inflammatory cytokines including TNF-α and IL-6, and has been shown to reduce intestinal inflammation in colitis models.

What makes KPV interesting for gut health is that it can be formulated for targeted intestinal delivery. Oral capsules can deliver KPV directly to the intestinal lining where inflammation is occurring. Typical dosing is 200-500 mcg orally once or twice daily.

KPV is particularly relevant for conditions driven by chronic inflammation: ulcerative colitis, Crohn's disease flares, and generalized intestinal inflammation. It does not directly repair tissue like BPC-157 — rather, it reduces the inflammatory environment that prevents healing.

LL-37 is a 37-amino-acid antimicrobial peptide that is part of the body's innate immune system. It is produced by immune cells, epithelial cells, and gut lining cells. LL-37 works differently from antibiotics — it physically disrupts bacterial cell membranes, making it effective against bacteria, fungi, and some viruses, including antibiotic-resistant strains.

For gut applications, LL-37 is relevant when gut dysfunction involves microbial imbalance (dysbiosis), small intestinal bacterial overgrowth (SIBO), or chronic gut infections that do not respond to conventional treatment.

LL-37 is typically administered subcutaneously at 50-100 mcg daily for 4-6 weeks. It has broader antimicrobial effects throughout the body and is not gut-specific, but its role in maintaining the gut barrier makes it relevant for intestinal health.

These three peptides address different layers of gut dysfunction and can be combined:

BPC-157 + KPV is the most common gut stack: BPC-157 repairs damaged tissue while KPV reduces the inflammation that caused the damage. This addresses both the symptom (damaged tissue) and one of the root causes (chronic inflammation).

Adding LL-37 makes sense when there is a suspected microbial component — chronic infections, SIBO, or post-antibiotic dysbiosis.

Supporting the peptide protocol with glutathione (a powerful endogenous antioxidant) can help reduce oxidative stress in the gut lining, which contributes to tissue damage in inflammatory conditions.

Gut conditions should be properly diagnosed before starting any peptide protocol. Symptoms like chronic abdominal pain, blood in stool, unexplained weight loss, or persistent diarrhea require medical evaluation — they can indicate serious conditions that peptides cannot treat.

BPC-157 has the most extensive (though still animal-based) research for gut applications. KPV and LL-37 have less published data specifically for gastrointestinal use. None have completed human clinical trials for gut indications.

Dietary factors (elimination of trigger foods, adequate fiber, reduced alcohol and NSAID use) should be addressed alongside any peptide protocol. Peptides can accelerate healing, but they cannot overcome ongoing damage from diet and lifestyle.